Welcome to our dedicated page for Aimfinity Investment I SEC filings (Ticker: AIMTF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Aimfinity Investment Corp. I (AIMTF) provide a detailed record of its activities as a Cayman Islands SPAC pursuing a business combination with Docter Inc. Through Forms 8-K, proxy statements, and other reports, the company explains its merger structure, extension mechanics, and shareholder redemption framework. This page centralizes those filings and pairs them with AI-powered summaries to help readers interpret the technical language.
Key documents include multiple Form 8-K reports describing the Agreement and Plan of Merger with Docter Inc., the two-step structure involving a reincorporation merger and an acquisition merger, and the approval of the Docter Business Combination at the March 27, 2025 extraordinary general meeting. Other 8-K filings outline the Extension Amendment and NTA Amendment, which extend the deadline to complete a business combination and remove a net tangible asset minimum that could otherwise restrict redemptions or closing.
Several 8-Ks and related exhibits also document unsecured promissory notes issued to the sponsor’s designee to fund Monthly Extensions by depositing fixed amounts into the trust account, along with an exchange agreement that allows any outstanding note balance to convert into PubCo ordinary shares upon closing of the business combination. A Form 12b-25 (NT 10-Q) filing explains a short delay in submitting a quarterly report and confirms the company’s intention to file within the permitted grace period.
On this filings page, you can review Aimfinity Investment Corp. I’s 8-Ks, proxy statement on Schedule 14A, notification of late filing, and other reports as they appear on EDGAR. AI-generated highlights help surface the main terms of the Docter Business Combination, the voting results on charter amendments, the structure of AIMTF units and warrants, and the conditions under which the SPAC may redeem public shares, extend its combination period, or proceed to liquidation if no transaction is completed.
Aimfinity Investment Corp. I reported shareholder approval of an amendment allowing extensions of its business combination deadline to October 28, 2025, with up to nine one‑month extensions to July 28, 2026 by depositing $500 per month. The company elected to extend to November 28, 2025 and deposited $500 into its trust account.
The company was informed that 572,989 Class A ordinary shares were tendered for redemption in connection with the extension process. In addition, 503,472 Class A ordinary shares remain subject to redemption upon the closing of the proposed business combination with Docter Inc., based on prior requests. The business combination had previously been approved at the March 27, 2025 meeting.
Aimfinity’s securities trade over-the-counter: units (AIMUF), new units (AIMTF), and Class 1 redeemable warrants (AIMWF), each warrant exercisable for one Class A ordinary share at an exercise price of $11.50.
Aimfinity Investment Corp. I reported shareholder approval of two charter amendments to keep its SPAC process moving. The extension amendment lets the company extend its business combination deadline by up to nine one‑month periods to July 28, 2026, with a deposit of $500 into the trust account for each extension. The NTA amendment removes the prior requirement to maintain net tangible assets of at least $5,000,001 in connection with redemptions or closing.
To fund the first extension from October 28, 2025 to November 28, 2025, the company issued a $500 unsecured promissory note to the sponsor’s designee, exchangeable at closing of the Docter Inc. business combination into PubCo ordinary shares at $10.00 per share. The extension proposal passed with 2,785,849 votes for, 2,097 against, 4 abstain; the NTA change passed with 2,787,946 for, 0 against, 4 abstain. As of September 29, 2025, shares outstanding were 1,758,476 Class A and 2,012,500 Class B.
Aimfinity Investment Corp. I filed an 8-K to supplement its proxy materials for the Extraordinary Meeting. The company extended the deadline for public shareholders to submit redemption requests or reversals from October 23, 2025, 5:00 p.m. ET to October 27, 2025, 11:00 a.m. ET.
The filing clarifies that holders who previously elected to redeem in connection with the Docter Business Combination must reverse or withdraw that prior request and then submit a new redemption election for this Extraordinary Meeting if they wish to redeem now. It also notes there is no assurance the meeting will be held if the Docter Business Combination is completed beforehand; any proposed closing date will be announced at least 2 business days in advance.
Meeting logistics are unchanged: the session remains on October 27, 2025 at the Taiwan location with virtual access. The record date remains September 29, 2025.
Aimfinity Investment Corp. I filed its 10-Q showing modest non-operating profits and significant balance sheet changes typical of a SPAC nearing its deadline. For the six months ended June 30, 2025, the company reported net income of $75,425, driven by $484,941 of interest on trust assets and $409,516 of formation and operating costs. For Q2, net income was $10,494.
Trust assets were $13,981,534 as of June 30, 2025, after the redemption of 1,996,522 Class A shares for $23,778,577. 1,116,476 ordinary shares were classified as redeemable at $12.52 each. Working capital showed a deficit of $2,515,028, and management disclosed “substantial doubt” about continuing as a going concern absent a business combination by the extended deadline.
The company continues to pursue its merger with Docter Inc. It converted $1,500,000 of sponsor loans into 150,000 private units on April 8, 2025, and restructured deferred IPO underwriting fees on June 13, 2025 to $80,000 cash plus 132,875 PubCo shares for each underwriter at closing. Extensions funded through deposits push the combination window to October 28, 2025.
Aimfinity Investment Corp. I called an extraordinary general meeting for October 27, 2025 to vote on three items: extending its deadline to complete the Docter Business Combination and permitting up to nine one‑month extensions to July 28, 2026; removing the $5,000,001 net tangible asset redemption floor; and a potential adjournment to gather more votes.
If the extension is approved, the Sponsor would deposit $500 into the trust for each monthly extension. As of the September 29, 2025 record date, the trust held approximately $14.29 million. The company estimates a redemption price of about $12.80 per share, subject to the trust’s actual value at redemption. Shareholders may redeem by submitting New Units; the Class 2 warrants attached to redeemed New Units will be forfeited.
Approval of the two amendments requires a two‑thirds special resolution of Class A and Class B shares voting together. If the extension is not approved and no business combination is completed by October 28, 2025, the company states it will redeem public shares and liquidate.
Aimfinity Investment Corp. I is changing how it will acquire Inkrock Holding Limited in connection with its planned business combination with Docter Inc. The company and related parties terminated a prior May 27, 2025 securities purchase agreement that would have transferred all of CEO I-Fa Chang’s Inkrock securities to PubCo in exchange for the immediate issuance of 687,054 ordinary shares.
Because that earlier transfer was never completed, the parties signed a termination agreement on October 6, 2025 and a new securities purchase agreement on October 7, 2025. Under the new arrangement, the same 687,054 ordinary shares will be issued to the seller, and all Inkrock securities will be transferred to PubCo, but both steps will occur simultaneously with the closing of the approved business combination, as an unregistered sale of equity securities.
Aimfinity Investment Corp. I is asking shareholders to approve a charter amendment that would extend its period to complete a business combination to October 28, 2025 and permit the Board, at the Sponsor's request, to approve up to nine additional one-month extensions through July 28, 2026. The company entered into a Merger Agreement with Docter Inc. that contemplates a reincorporation merger into a Cayman Islands PubCo and an acquisition merger resulting in PubCo as the surviving public company.
The proxy explains redemption mechanics: public shareholders may redeem shares for a pro rata cash amount from the Trust Account (including interest) if the Charter Amendment is approved, with attached Class 2 warrants forfeited on redemption. The filing discloses Trust Account funding from the IPO (gross proceeds cited at $80.5 million and $82,110,000 placed in trust) and that an F-4 related to the Docter Business Combination was declared effective by the SEC.
Aimfinity Investment Corp. I entered into a new unsecured promissory note of $55,823.8 on September 28, 2025 with I-Fa Chang, the designee of its sponsor, to fund a required deposit into its trust account.
This deposit of $55,823.8 equals $0.05 per public share for a one-month extension and allows Aimfinity to extend the deadline to complete its business combination with Docter Inc. from September 28, 2025 to October 28, 2025. This is the last of up to nine monthly extensions permitted under its charter.
Under an exchange agreement, the outstanding balance of the Extension Note will automatically convert into PubCo ordinary shares at $10.00 per share upon closing of the business combination, unless repaid earlier. The note was issued as an unregistered security under Section 4(a)(2) of the Securities Act, and the company furnished a press release announcing the new extension.